Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024
Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines for hypertension, chronic kidney disease and aldosterone-related disorders, has scheduled its Q3 2024 financial results announcement for November 11, 2024, after market close. The company will host a conference call at 4:30 p.m. ET on the same day, accessible via domestic (1-877-407-9127) and international (1-201-689-8574) dial-in numbers. A live webcast will be available through the company's Investor Relations website.
Mineralys Therapeutics (NASDAQ: MLYS), un'azienda biofarmaceutica in fase clinica focalizzata nello sviluppo di farmaci per l'ipertensione, la malattia renale cronica e i disturbi correlati all'aldosterone, ha programmato l'annuncio dei suoi risultati finanziari del Q3 2024 per l'11 novembre 2024, dopo la chiusura del mercato. L'azienda ospiterà una conference call alle 16:30 ET dello stesso giorno, accessibile tramite numeri di accesso domestici (1-877-407-9127) e internazionali (1-201-689-8574). Una trasmissione in diretta sarà disponibile attraverso il sito web delle relazioni con gli investitori dell'azienda.
Mineralys Therapeutics (NASDAQ: MLYS), una compañía biofarmacéutica en etapa clínica centrada en el desarrollo de medicamentos para la hipertensión, la enfermedad renal crónica y los trastornos relacionados con la aldosterona, ha programado el anuncio de sus resultados financieros del Q3 2024 para el 11 de noviembre de 2024, después del cierre del mercado. La compañía llevará a cabo una conferencia telefónica a las 4:30 p.m. ET el mismo día, accesible a través de números de marcación nacionales (1-877-407-9127) e internacionales (1-201-689-8574). Se dispondrá de una transmisión en vivo a través del sitio web de Relaciones con Inversionistas de la empresa.
미네랄리스 테라퓨틱스(Mineralys Therapeutics) (NASDAQ: MLYS)는 고혈압, 만성 신장 질환, 알도스테론 관련 질환을 위한 의약품 개발에 중점을 둔 임상 단계의 생명공학 회사로, 2024년 3분기 재무 결과 발표를 2024년 11월 11일, 시장 마감 후로 예정하고 있습니다. 회사는 같은 날 동부 표준시 오후 4시 30분에 전화 회의를 개최할 예정이며, 국내(1-877-407-9127) 및 국제(1-201-689-8574) 가입 전화번호를 통해 접속할 수 있습니다. 회사의 투자자 관계 웹사이트를 통해 실시간 웹 캐스트도 제공될 예정입니다.
Mineralys Therapeutics (NASDAQ: MLYS), une société biopharmaceutique en phase clinique axée sur le développement de médicaments pour l'hypertension, la maladie rénale chronique et les troubles liés à l'aldostérone, a prévu l'annonce de ses résultats financiers du T3 2024 pour le 11 novembre 2024, après la fermeture des marchés. La société organisera une conférence téléphonique à 16h30, heure de l'Est, le même jour, accessible par les numéros de téléphone domestiques (1-877-407-9127) et internationaux (1-201-689-8574). Une diffusion en direct sera disponible via le site web des relations avec les investisseurs de l'entreprise.
Mineralys Therapeutics (NASDAQ: MLYS), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das sich auf die Entwicklung von Medikamenten gegen Bluthochdruck, chronische Nierenerkrankungen und aldosteronbedingte Störungen konzentriert, hat die Bekanntgabe seiner Finanzergebnisse für das dritte Quartal 2024 für den 11. November 2024, nach Börsenschluss, angesetzt. Das Unternehmen wird am selben Tag um 16:30 Uhr ET eine Telefonkonferenz abhalten, die über nationale (1-877-407-9127) und internationale (1-201-689-8574) Telefonnummern zugänglich ist. Ein Live-Stream wird über die Investor Relations-Website des Unternehmens verfügbar sein.
- None.
- None.
RADNOR, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the third quarter ended September 30, 2024, after the financial markets close on Monday, November 11, 2024.
| Monday, November 11th @ 4:30 p.m. ET | |
| Domestic: | 1-877-407-9127 |
| International: | 1-201-689-8574 |
| Webcast: | Link |
A live webcast of the conference call may also be found on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com
FAQ
When will Mineralys Therapeutics (MLYS) release Q3 2024 earnings?
How can I access Mineralys Therapeutics (MLYS) Q3 2024 earnings call?
What therapeutic areas does Mineralys Therapeutics (MLYS) focus on?
